FAU

FAU ubiquitin like and ribosomal protein S30 fusion P62861 RS30_HUMAN
Protein Coding Chr 11 11q13.1 Swiss-Prot reviewed Entrez 2197
Mutations
314
CL 63 · Tissue 245
Samples
70
CL 17 · Tissue 52
Peptides
70
unique mutant peptides
Transcripts
7
isoforms mutated

Stats by Source

Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)

How the counts split by source
Stats by Source

Total = all mutations for this gene across every source.

Cell line = COSMIC Cell Lines Project + DepMap + PubMed.

Tissue = COSMIC primary-tissue (patient tumour) samples.

Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.

TotalCell lineTissue
Mutations31463245
Samples701752
Peptides701360

Function

FAU · FAU ubiquitin like and ribosomal protein S30 fusion

This gene is the cellular homolog of the fox sequence in the Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV). It encodes a fusion protein consisting of the ubiquitin-like protein fubi at the N terminus and ribosomal protein S30 at the C terminus. It has been proposed that the fusion protein is post-translationally processed to generate free fubi and free ribosomal protein S30. Fubi is a member of the ubiquitin family, and ribosomal protein S30 belongs to the S30E family of ribosomal proteins. Whereas the function of fubi is currently unknown, ribosomal protein S30 is a component of the 40S subunit of the cytoplasmic ribosome and displays antimicrobial activity. Pseudogenes derived from this gene are present in the genome. Similar to ribosomal protein S30, ribosomal proteins S27a and L40 are synthesized as fusion proteins with ubiquitin. [provided by RefSeq, Nov 2014].

Isoforms & Proteins

7 transcripts · UniProt mapping is sequence-verified (AA-safe)

About the isoform mapping
Isoforms & Proteins

Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.

The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.

Counts are mutations and unique mutant peptides on each transcript.

TranscriptUniProtMutationsPeptides
ENST00000529639 P62861 67 52
ENST00000527548 P62861 59 49
ENST00000531743 P62861 59 49
ENST00000525297 E9PR30* 43 37
ENST00000279259 J3KN89* 34 28
ENST00000434372 E9PMS9* 26 22
ENST00000529259 E9PMS9* 26 22

Gene Properties

Type
Protein Coding
Chromosome
11
Cytoband
11q13.1
Entrez ID
Aliases
FAU1Fub1FubiMNSFbetaRPS30S30

Recurrent Mutations

All 52 amino-acid changes on canonical ENST00000529639 · needle height = samples · drag the mini-map to zoom

What this lollipop shows
Recurrent Mutations

A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).

X-axis = amino-acid position in the protein.

Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.

The most recurrent changes are labelled; hover any needle for the change, position and counts.

Mutation frequency across cancer types

% of samples with a missense/complex mutation in FAU · cell line vs tissue

How this frequency is counted
Cancer-type mutation frequency

For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FAU – counted as distinct samples (a sample counts once no matter how many mutations it has).

Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.

Cancer typeCell linesTissue samples
Chronic Myelogenous Leukemia
2/25 8%
0/0 0%
T-Lymphoblastic Leukemia
1/40 2%
0/0 0%
Germ Cell Tumour
0/25 0%
1/169 1%
Osteosarcoma
1/45 2%
0/166 0%
Colorectal Carcinoma
4/143 3%
12/3239 0%
Endometrial Carcinoma
1/42 2%
2/612 0%
Neuroendocrine Tumour
2/154 1%
1/577 0%
Melanoma
1/210 0%
6/1899 0%
Ewings Sarcoma
1/63 2%
0/262 0%
Biliary Tract Carcinoma
0/54 0%
3/950 0%
Cervical Carcinoma
0/35 0%
1/422 0%
Medulloblastoma
0/0 0%
1/450 0%
Kidney Carcinoma
0/85 0%
4/1862 0%
Bladder Carcinoma
0/58 0%
2/956 0%
Non-Small Cell Lung Carcinoma
2/304 1%
1/1390 0%
Pancreatic Carcinoma
0/89 0%
3/1611 0%
Hepatocellular Carcinoma
0/46 0%
4/2210 0%
Other Sarcomas
0/69 0%
1/699 0%
Squamous Cell Lung Carcinoma
0/57 0%
1/810 0%
Breast Carcinoma
2/144 1%
2/3264 0%
Other Solid Cancers
0/94 0%
2/1515 0%
Ovarian Carcinoma
0/109 0%
1/998 0%
B-Cell Non-Hodgkins Lymphoma
0/88 0%
2/2534 0%
Thyroid Gland Carcinoma
0/45 0%
1/1592 0%
Gastric Carcinoma
0/74 0%
1/1809 0%
Glioma
0/52 0%
1/2127 0%

Mutation Distribution

Where FAU is mutated · all tissues, split by cell line vs tissue

Mutation counts by tissue
Mutation Distribution

How many mutations in FAU were found in each tissue, across the whole database.

Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.

This shows the cancer-context where this gene is recurrently altered.

GTEx Expression

Median TPM across 54 healthy tissues

GTEx Portal ↗
About the expression data
GTEx Expression

Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.

Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.

Scroll or drag the mini-axis below the chart to browse all tissues.

Mutations

All 314 mutations in FAU

About the mutation list
Mutations

Every mutation record for this gene, across all samples and sources.

The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).

Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.

IDSampleTranscriptAA Change CDSTypeSourceMutant PeptideWild-type Peptide